Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

McGill University

$105,000.00

Osteopontin promotes breast cancer recurrence by establishing an inflammatory and fibrotic tumour microenvironment mediated by pro-tumourigenic macrophages and cancer-associated fibroblasts

EF 2022-23

Résumé
Breast cancer has one of the most promising prognoses yet remains the second deadliest cancer for one in eight Canadian women. Its morbidity is largely attributed to malignancies returning in patients, most of whom will eventually succumb and die from cancer recurrence. Some tumours enter a state of dormancy. Dormant tumours can bypass standard therapies and remain clinically undetected from months to decades. Eventually, they "wake up" to cause relapse and can spread aggressively to distant organs. Recurrent cancer often confers resistance to cancer cell-targeted therapy and develop at an accelerated rate, hence persisting as the main hurdle in current breast cancer treatment. The mechanisms behind such processes remain to be understood, highlighting the importance of our study to unveil tumour environmental factors that govern this process. My research investigates the extrinsic mechanisms behind tumour dormancy and recurrence: which non-cancer cells help tumours recur and how do they do it? Here, we use a genetically engineered mouse model to mirror breast cancer dormancy and recurrence in human disease. Characterization of our model revealed that recurrent tumours benefit from selective immune cells mediated by a secreted factor called osteopontin while also shifting the acellular components of the tumour environment. Therefore, cancer cells and non-cancer cells collectively establish a favourable setting for successful recurrence. Forty percent of breast cancer patients experience cancer recurrence with a survival rate barely half of those who do not. This is largely attributed to the lack of alternative therapies for these drug-resistant and aggressive tumours. Our study will reveal novel targets for immunotherapy that can synergize with current treatments to avert breast cancer recurrence and improve patient outcome.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
475794
Name
Gu Yu
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Osteopontin promotes breast cancer recurrence by establishing an inflammatory and fibrotic tumour microenvironment mediated by pro-tumourigenic macrophages and cancer-associated fibroblasts
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Cancer Recurrence; Cancer-Associated Fibroblasts; Extracellular Matrix; Genetically Engineered Mouse Model; Immune Regulation; Invadopodia; Osteopontin; Tumour Dormancy; Tumour Microenvironment
Abstract
Breast cancer has one of the most promising prognoses yet remains the second deadliest cancer for one in eight Canadian women. Its morbidity is largely attributed to malignancies returning in patients, most of whom will eventually succumb and die from cancer recurrence. Some tumours enter a state of dormancy. Dormant tumours can bypass standard therapies and remain clinically undetected from months to decades. Eventually, they "wake up" to cause relapse and can spread aggressively to distant organs. Recurrent cancer often confers resistance to cancer cell-targeted therapy and develop at an accelerated rate, hence persisting as the main hurdle in current breast cancer treatment. The mechanisms behind such processes remain to be understood, highlighting the importance of our study to unveil tumour environmental factors that govern this process. My research investigates the extrinsic mechanisms behind tumour dormancy and recurrence: which non-cancer cells help tumours recur and how do they do it? Here, we use a genetically engineered mouse model to mirror breast cancer dormancy and recurrence in human disease. Characterization of our model revealed that recurrent tumours benefit from selective immune cells mediated by a secreted factor called osteopontin while also shifting the acellular components of the tumour environment. Therefore, cancer cells and non-cancer cells collectively establish a favourable setting for successful recurrence. Forty percent of breast cancer patients experience cancer recurrence with a survival rate barely half of those who do not. This is largely attributed to the lack of alternative therapies for these drug-resistant and aggressive tumours. Our study will reveal novel targets for immunotherapy that can synergize with current treatments to avert breast cancer recurrence and improve patient outcome.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Gu, Yu
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~